TY - JOUR
T1 - Probing the therapeutic potential of TRPC6 for Alzheimer's disease in live neurons from patient-specific iPSCs
AU - Tao, Ran
AU - Lu, Rui
AU - Wang, Junfeng
AU - Zeng, Shujun
AU - Zhang, Ting
AU - Guo, Wenke
AU - Zhang, Xiaobing
AU - Cheng, Qi
AU - Yue, Chunmei
AU - Wang, Yizheng
AU - Jing, Naihe
N1 - Publisher Copyright:
© 2020 The Author(s) (2020). Published by Oxford University Press on behalf of Journal of Molecular Cell Biology, IBCB, SIBS, CAS.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - The induced pluripotent stem cells (iPSCs) offer an unprecedented opportunity to model and study Alzheimer's disease (AD) under patient-specific genetic background. The lower expression of transient receptor potential canonical 6 (TRPC6) was associated with AD patients, which might be involved in AD pathogenesis. However, the role of TRPC6 that played in AD process still needs more investigation in patient-relevant neurons. In this study, the iPSCs were generated from peripheral blood cells of sporadic AD patients and efficiently differentiated into mature cortical neurons. These sporadic AD-bearing neurons displayed higher levels of AD pathological markers Aβ and phospho-tau, but lower levels of TRPC6, than those of control neurons. Treatment of AD neurons with TRPC6 protein fragment or agonist inhibited the elevation of Aβ and phospho-tau. Our results in live AD neurons manifest that the compromised expression of TRPC6 substantially contributed to Aβ pathology of sporadic AD, suggesting that targeting TRPC6 could help to develop novel therapeutic strategies for the treatments of AD.
AB - The induced pluripotent stem cells (iPSCs) offer an unprecedented opportunity to model and study Alzheimer's disease (AD) under patient-specific genetic background. The lower expression of transient receptor potential canonical 6 (TRPC6) was associated with AD patients, which might be involved in AD pathogenesis. However, the role of TRPC6 that played in AD process still needs more investigation in patient-relevant neurons. In this study, the iPSCs were generated from peripheral blood cells of sporadic AD patients and efficiently differentiated into mature cortical neurons. These sporadic AD-bearing neurons displayed higher levels of AD pathological markers Aβ and phospho-tau, but lower levels of TRPC6, than those of control neurons. Treatment of AD neurons with TRPC6 protein fragment or agonist inhibited the elevation of Aβ and phospho-tau. Our results in live AD neurons manifest that the compromised expression of TRPC6 substantially contributed to Aβ pathology of sporadic AD, suggesting that targeting TRPC6 could help to develop novel therapeutic strategies for the treatments of AD.
KW - Alzheimer's disease
KW - amyloid-beta (Aβ)
KW - cellular models
KW - patient-specific induced pluripotent stem cells (iPSCs)
KW - transient receptor potential canonical 6 (TRPC6)
UR - http://www.scopus.com/inward/record.url?scp=85100224083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100224083&partnerID=8YFLogxK
U2 - 10.1093/jmcb/mjaa027
DO - 10.1093/jmcb/mjaa027
M3 - Review article
C2 - 32492143
SN - 1674-2788
VL - 12
SP - 807
EP - 816
JO - Journal of Molecular Cell Biology
JF - Journal of Molecular Cell Biology
IS - 10
ER -